Astellas Pharma Europe B.V.
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Astellas Pharma Europe B.V. sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Astellas Pharma Europe B.V.: 12 sponsored US clinical trials, none currently recruiting.
Astellas Pharma Europe B.V. sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 7 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Systemic Fungal Infections, with 1 trials.
Top-decile sponsor footprint
Astellas Pharma Europe B.V. ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
12 total, page 1 of 1
A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects
NCT04742517
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
NCT02302079
A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
NCT02218372
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
NCT02045862
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
NCT01972841
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
NCT01981954
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
NCT01902251
A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076
NCT01655069
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
NCT01686607
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
NCT01565694
A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug
NCT01565707
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
NCT00902928
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 7 |
Therapeutic Areas
How the Astellas Pharma Europe B.V. archive is shaped
12 indexed studies, none listed as recruiting (0% open); 12 completed (100%).
Phase mix: 7 late (III/IV) vs 4 early (I/II) (later-stage heavy).
Top condition: Systemic Fungal Infections (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Astellas Pharma Europe B.V.: archived-pipeline peers nationwide
Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Astellas Pharma Europe B.V. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 archived trials
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Astellas Pharma Europe B.V. page
12 registered trials is a research-attention snapshot, not an endorsement of Astellas Pharma Europe B.V. or any single study.
- None of Astellas Pharma Europe B.V.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Systemic Fungal Infections is the condition Astellas Pharma Europe B.V. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Systemic Fungal Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Astellas Pharma Europe B.V. pipeline card: 12 registered trials from official public datasets.Report a data error.